Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Golidocitinib in R/R PTCL
NCT06757387Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Peking University Cancer Hospital & Institute. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06757387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757387.